ATE255589T1 - Kristallin form i von clarithromycin - Google Patents

Kristallin form i von clarithromycin

Info

Publication number
ATE255589T1
ATE255589T1 AT97934307T AT97934307T ATE255589T1 AT E255589 T1 ATE255589 T1 AT E255589T1 AT 97934307 T AT97934307 T AT 97934307T AT 97934307 T AT97934307 T AT 97934307T AT E255589 T1 ATE255589 T1 AT E255589T1
Authority
AT
Austria
Prior art keywords
clarithromycin
crystalline form
methylerythromycin
antiobiotic
novel
Prior art date
Application number
AT97934307T
Other languages
English (en)
Inventor
Jih-Hua Liu
David A Riley
Stephen G Spanton
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24736505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE255589(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE255589T1 publication Critical patent/ATE255589T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97934307T 1996-07-29 1997-07-25 Kristallin form i von clarithromycin ATE255589T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/681,723 US5858986A (en) 1996-07-29 1996-07-29 Crystal form I of clarithromycin
PCT/US1997/013128 WO1998004573A1 (en) 1996-07-29 1997-07-25 Crystal form i of clarithromycin

Publications (1)

Publication Number Publication Date
ATE255589T1 true ATE255589T1 (de) 2003-12-15

Family

ID=24736505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934307T ATE255589T1 (de) 1996-07-29 1997-07-25 Kristallin form i von clarithromycin

Country Status (18)

Country Link
US (1) US5858986A (de)
EP (1) EP0915898B1 (de)
JP (2) JP2000515894A (de)
KR (1) KR100498800B1 (de)
CN (2) CN1216892C (de)
AT (1) ATE255589T1 (de)
AU (1) AU3739797A (de)
BR (1) BR9710768A (de)
CA (2) CA2258606C (de)
CZ (1) CZ294446B6 (de)
DE (1) DE69726577T2 (de)
DK (1) DK0915898T3 (de)
ES (1) ES2173056T3 (de)
IL (1) IL127581A (de)
NZ (1) NZ333380A (de)
PT (1) PT915898E (de)
TR (1) TR199900083T2 (de)
WO (1) WO1998004573A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
WO2000077017A1 (en) * 1999-06-11 2000-12-21 Ranbaxy Laboratories Limited Novel amorphous form of clarithromycin
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
WO2001044262A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
AU2001222619C1 (en) 2000-01-11 2006-01-12 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1313486A1 (de) 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung des clarithromycins und eines clarithromycin-zwischenprodukt; clarithromycin wesentlich frei von oxime; und pharmazeutische zusammensetzung die sie enthalten
MXPA02008861A (es) * 2000-03-15 2003-02-10 Hanmi Pharm Ind Co Ltd Metodo para preparar claritromicina de cristales de forma ii.
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
KR20000037126A (ko) * 2000-04-08 2000-07-05 김용규 6-메틸 에리스로마이신 ａ의 제조방법
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
CA2425688A1 (en) * 2000-10-13 2002-05-16 Donald J. Treacy Jr. Extended release erythromycin derivatives
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1653925A1 (de) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
AU2005269981A1 (en) * 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (de) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
CN101525360B (zh) * 2008-03-06 2012-10-10 刘力 大环内酯类有机酸盐的水合物及其制备和用途
CN101812102B (zh) * 2009-02-21 2015-09-02 王凌峰 6-o-甲基红霉素a晶型v
CN102532222B (zh) * 2010-12-21 2015-06-17 北大方正集团有限公司 一种麦迪霉素的结晶方法
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN102942607A (zh) * 2012-11-28 2013-02-27 宁夏启元药业有限公司 一种复合溶剂结晶红霉素的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
EP0260938B1 (de) 1986-09-18 1992-12-09 Taisho Pharmaceutical Co. Ltd Erythromycin-A-Derivate und Verfahren zu ihrer Herstellung
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
JP2782793B2 (ja) * 1988-06-15 1998-08-06 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US5872229A (en) * 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives

Also Published As

Publication number Publication date
CN1216892C (zh) 2005-08-31
ES2173056T1 (es) 2002-10-16
EP0915898B1 (de) 2003-12-03
CA2258606C (en) 2003-05-27
CA2627035A1 (en) 1998-02-05
CN1229411A (zh) 1999-09-22
TR199900083T2 (xx) 1999-04-21
BR9710768A (pt) 1999-08-17
KR20000029644A (ko) 2000-05-25
ES2173056T3 (es) 2004-06-16
JP2000515894A (ja) 2000-11-28
KR100498800B1 (ko) 2005-07-01
IL127581A (en) 2004-06-20
PT915898E (pt) 2004-02-27
AU3739797A (en) 1998-02-20
DK0915898T3 (da) 2004-02-16
CN1754884A (zh) 2006-04-05
IL127581A0 (en) 1999-10-28
JP5290136B2 (ja) 2013-09-18
CA2258606A1 (en) 1998-02-05
DE69726577D1 (en) 2004-01-15
NZ333380A (en) 2000-01-28
EP0915898A1 (de) 1999-05-19
CZ294446B6 (cs) 2005-01-12
JP2010090156A (ja) 2010-04-22
WO1998004573A1 (en) 1998-02-05
CZ9999A3 (cs) 1999-05-12
DE69726577T2 (de) 2004-11-04
US5858986A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
ATE255589T1 (de) Kristallin form i von clarithromycin
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
CA2277274A1 (en) Crystal form 0 of clarithromycin
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
AP2002002458A0 (en) Compounds for the treatment of ischemia.
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
NO980317L (no) Anvendelse av Calendula-glykosider for behandling av psoriasis
NO971625L (no) Nye peptider med immunomodulatoriske effekter
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
FI960316A7 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät fa rmaseuttiset koostumukset
DE69709891D1 (de) Chitosan enthaltende zusammensetzung
CA2386527A1 (en) Crystal form i of clarithromycin
CA2386534A1 (en) Crystal form ii of clarithromycin and uses thereof
BR9902081A (pt) Combinação de dofetilida e um bloqueador dos canais de cálcio
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0915898

Country of ref document: EP

RZN Patent revoked